Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Meningioma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

CNS Tumor (591)

Brain Cancer (583)

Neuroblastoma (59)

Pituitary Gland Carcinoma (10)

CNS Tumor (591)

Brain Cancer (583)

Neuroblastoma (59)

Pituitary Gland Carcinoma (10)

›

No biomarker	Meningioma	No biomarker	Meningioma	bevacizumab + everolimus Sensitive: A2 - Guideline bevacizumab + everolimus Sensitive : A2	bevacizumab + everolimus Sensitive: A2 - Guideline bevacizumab + everolimus Sensitive : A2
No biomarker	Meningioma	No biomarker	Meningioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Meningioma	No biomarker	Meningioma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Meningioma	No biomarker	Meningioma	DG3173 Sensitive: A2 - Guideline DG3173 Sensitive : A2	DG3173 Sensitive: A2 - Guideline DG3173 Sensitive : A2
SMO P641A	Meningioma	SMO P641A	Meningioma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
NF2 mutation	Meningioma	NF2 mutation	Meningioma	GSK2256098 Sensitive: C3 – Early Trials GSK2256098 Sensitive : C3	GSK2256098 Sensitive: C3 – Early Trials GSK2256098 Sensitive : C3
RB1 mutation	Meningioma	RB1 mutation	Meningioma	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
KLF4 K409Q	Meningioma	KLF4 K409Q	Meningioma	temsirolimus Sensitive: D – Preclinical temsirolimus Sensitive : D	temsirolimus Sensitive: D – Preclinical temsirolimus Sensitive : D